- With nearly three decades of experience in emerging companies, Bienaimé is well-positioned to help Ovkin discover and develop new and better drugs and diagnostics at scale.
- Under his leadership as Chairman and CEO from 2005 to 2023, BioMarin’s market capitalization increased from $400 million to $18 billion.
- Mr. Bienaimé currently serves on the boards of directors of Incyte, Immunome and the Biotechnology Industry Organization
PARIS–(BUSINESS WIRE)–The third point of the subtitle should read: Mr. Bynaime currently serves on the boards of directors of Insight, Immunom and the Biotechnology Industry Organization (replacing Mr. Bynaime who currently serves on the boards of directors of Insight, Key Therapeutics, Inc. and the Biotechnology Industry Organization).
The updated version says:
Jean-Jacques Bianaime was appointed President of the Ovkin Council
- With nearly three decades of experience in emerging companies, Bienaimé is well-positioned to help Ovkin discover and develop new and better drugs and diagnostics at scale.
- Under his leadership as Chairman and CEO from 2005 to 2023, BioMarin’s market capitalization increased from $400 million to $18 billion.
- Mr. Bienaimé currently serves on the boards of directors of Incyte, Immunome and the Biotechnology Industry Organization
of OakTechBio is pleased to announce the appointment of Jean-Jacques Bienaimé as Chairman of its Board of Directors, combining the best of humans and artificial intelligence to find the right treatment for each patient.
Bienaimé joined BioMarin in May 2005, when the company had a commercialized product and about $26 million in annual revenue. Mr. Under Bienaimé’s leadership, BioMarin grew significantly, driven by the company’s world-leading enzyme replacement therapy business. During his tenure, Mr. Bienaimé led the significant expansion of BioMarin’s workforce, from approximately 300 employees exclusively in the United States to today more than 3,400 people in nearly 80 countries worldwide.
„We are delighted to have Jean Jacques Bienaimé join our Board of Directors as our new Chairman,” said Thomas Clozel, MD, Co-Founder and CEO of Owkin. “With nearly three decades of experience as a CEO, Mr. Baineime’s proven track record and visionary leadership will drive innovation and drive sustainable growth for the benefit of all stakeholders. Together, we will pioneer innovative solutions to shape the future of biotechnology.
“Today we see information technology and biotechnology converging. I believe Ovekin is well-positioned to become a leader in the use of artificial intelligence to accelerate the development of diagnostics and precision medicine,” said Jean-Jacques Bynaime. „I am always interested in engaging with companies with innovative technologies that can make a significant difference in healthcare and patients’ lives, and Ovekin finds the right treatment for each patient. I want to continue working.”
Prior to joining BioMarin, Mr. Bienaimé has spent several years in similar executive roles at other pharmaceutical and biotechnology companies and currently serves on the boards of directors of Incyte, Immunome and the Biotechnology Industry Organization. Mr. Bienaimé studied economics at Paris Business School and received an MBA from the University of Pennsylvania.
Mr. Bienaimé joins a board of directors led by experienced biopharma industry figures and leading venture capital funds.
About Oak
of Oak It is the first full TechBio Unicorn with a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify diagnostic methods using AI trained on world-class patient data to deliver precision treatments, de-risk and accelerate clinical trials, and privacy-enhancing technologies. We combine wet lab experiments with advanced artificial intelligence techniques to create a powerful feedback loop to accelerate discovery and innovation in oncology, cardiovascular disease, immunity and inflammation. Ovkin also established Mosaic, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications. Ovkin has raised more than $300 million through investments from leading biopharmaceutical companies including Sanofi and PMS, as well as venture funds such as Fidelity, GV and PPFrance.
contact
Stephanie Libus, [email protected]
